Autopsy report · NCT02536300
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Cause of deathFunding or business
“Gilead has made the decision to close the study due to enrollment challenges”
Life of this trial
- Registered 5 months before it started.
- Ran for about 6 years 8 months before it stopped.
- 96 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Follicular Lymphoma
- Interventions
- Idelalisib
- Participants
- 96
- Sites
- 66
- Countries
- Australia, Canada, Czechia, France, Israel, Italy, Poland, Romania, Spain, United Kingdom
Trials that died the same way
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors
“Gilead decision to terminate” - COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
“The study was closed due to continued enrollment hurdles.” - Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
“Company decision to closing study and discontinue further patient enrollment.” - The Metabolomics of Anaphylaxis
“We are closing the study because of lack of enrollment.” - Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
“This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.